Simon Sturge - 01 Oct 2023 Form 4 Insider Report for MoonLake Immunotherapeutics (MLTX)

Role
Director
Signature
/s/ Matthias Bodenstedt, Attorney-in-fact for Simon Sturge
Issuer symbol
MLTX
Transactions as of
01 Oct 2023
Net transactions value
$0
Form type
4
Filing time
03 Oct 2023, 19:34:12 UTC
Previous filing
12 Jun 2023
Next filing
07 Jun 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MLTX Class A ordinary shares, par value $0.0001 per share Conversion of derivative security +342,980 342,980 01 Oct 2023 Direct F1, F2
transaction MLTX Class C ordinary shares, par value $0.0001 per share Disposed to Issuer -342,980 -100% 0 01 Oct 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MLTX Common shares, par value CHF 0.10 per share, of MoonLake AG Conversion of derivative security -10,196 -100% 0 01 Oct 2023 Class A ordinary shares, par value $0.0001 per share 342,980 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On October 1, 2023, the Reporting Person exchanged 10,196 common shares of MoonLake Immunotherapeutics AG ("MoonLake AG") for 342,980 Class A ordinary shares of the Issuer. In connection with the exchange, 342,980 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration.
F2 The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.